Best Low Price Stocks To Buy For 2014

It’s usually a sign of underlying buying interest in a stock, when it gains in price on a day when the overall market is negative, suggests John Dobosz, editor of Forbes Dividend Investor.

That’s what happened recently with Switzerland-based Transocean (RIG), the world’s largest offshore contract driller for oil and gas wells.

There’s a lot to like about Transocean these days. Last month, it struck a deal with Carl Icahn, who owns nearly 6% of the company, and was agitating for a number of changes.

He got another one of his people on the board of directors, and Transocean also cut the number of board seats from 14 to 11, giving existing members greater weight. Icahn also extracted a pledge that Transocean will boost profits by $800 million, through cost cutting, and increased efficiency.

Most significant for dividend investors is that Icahn succeeded in getting the company to agree to pay a $3 per share dividend next year, up 33.4% from the current $2.24 annual rate. Transocean will also explore spinning off some of its assets into a master limited partnership structure.

Best Low Price Stocks To Buy For 2014: The AES Corporation(AES)

The AES Corporation, through its subsidiaries, operates as a power company in Latin America, Africa, North America, Europe, the Middle East, and Asia. The company owns and operates two businesses, Generation and Utilities. The Generation business owns and/or operates power plants to generate and sell power to wholesale customers, such as utilities and other intermediaries. It generates electricity through various sources, including coal, gas, fuel oil, biomass, hydroelectric, wind, and solar. The Utilities business owns and/or operates utilities to distribute, transmit, and sell electricity to end-user customers in the residential, commercial, industrial, and governmental sectors. As of December 31, 2010, the company owned electricity generation and distribution facilities with a total capacity of approximately 40,500 megawatts and distribution networks serving approximately 12 million people in 28 countries. The AES Corporation was founded in 1981 and is based in Arlingto n, Virginia.

Advisors’ Opinion:

  • [By David Dittman]

    TECO Energy Inc (NYSE: TE), a member of the UF Dividend Watch List, was highest at 94.6 percent. AES Corp (NYSE: AES), the January 2014 UF Growth Spotlight, was lowest at 12.4 percent.

  • [By David Dittman]

    In November 2013, management at AES Corp. (AES) announced a 25% increase in its quarterly dividend rate to $0.05 per share, validating its efforts to turn the company around. But the work is far from over.

Best Low Price Stocks To Buy For 2014: Salix Pharmaceuticals Ltd (SLXP)

Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company’s products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Xifaxan (rifaximin) tablets

Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers’ diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.

It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.

In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla’s application related to amorphous rifaximin and Solmag SpA’s application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in ad dition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.

MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution

MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.

Apriso (mesalamine) extended-release capsu les 0.375 gram

Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product’s prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.

Relistor (methylnaltrexone bromide)

Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.

OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets

Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.

Solesta

Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.

Deflux

Deflux i s a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.

Fulyzaq (crofelemer) delayed-release tablets

On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.

Giazo (balsalazide disodium) tablets

February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.

Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets

METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.

Azasan (azathioprine) tablets

Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.

Anusol-HC and Proctocort (hydrocortisone) creams and suppositories

The Company acquired t he right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.

Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)

Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.

Colazal (balsalazide disodium) capsules

The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.

The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.

Advisors’ Opinion:

  • [By David Williamson]

    In this segment, health-care analyst David Williamson takes a look at the upcoming acquisition by Salix Pharmaceuticals (NASDAQ: SLXP  ) of Santarus (NASDAQ: SNTS  ) for about $2.6 billion. Salix is currently a maker of drugs for gastrointestinal diseases, and the immediately accretive deal will give Salix access to treatments for both diabetes and heartburn. Shares of both companies were up significantly on the news. David tells investors why shareholders should be pleased with this deal on both ends and what he thinks of the stock going forward.

  • [By Jake L’Ecuyer]

    Equities Trading UP
    Santarus (NASDAQ: SNTS) shot up 37.95 percent to $32.03 after Salix Pharmaceuticals (NASDAQ: SLXP) announced its plans to buy Santarus for around $2.12 billion. Santarus and Pharming also announced new data from open-label repeat treatment study with RUCONEST.

  • [By Paul Ausick]

    Stocks on the Move: Twitter Inc. (NYSE: TWTR) is down 7.3% at $41.64 on its second day of trading and word is that some hedge funds and traders are looking to borrow shares. Santarus Inc. (NASDAQ: SNTS) is up 37.6% at $31.95 after agreeing late Thursday night to an acquisition by Salix Pharmaceuticals Inc. (NASDAQ: SLXP) for $2.6 billion in cash.

Best Low Price Stocks To Buy For 2014: ChemoCentryx Inc (CCXI)

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK’786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company’s wholly owned subsidiary is ChemoCentryx Limited.

The Company’s drug candidate Traficet-EN (CCX282, GSK’786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Co mpany has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company’s Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).

The Company’s independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.

CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised it s option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.

CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).

The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.

Advisors’ Opinion:

  • [By James E. Brumley]

    The last few weeks haven’t been particularly encouraging for Crohn’s disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn’s drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn’t dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn’t look good. Then this month – just a few days ago – Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn’s disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn’t completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn’s sufferers don’t need to give up home just yet, however – TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn’s treatment that works, and should be able to sidestep the problems that pl agued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.

  • [By CRWE]

    ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.

Best Low Price Stocks To Buy For 2014: Gildan Activewear Inc.(GIL)

Gildan Activewear Inc. engages in the manufacture and sale of apparel products primarily in the United States, Canada, and Europe. It sells T-shirts, fleece, and sport shirts to wholesale distributors under the Gildan brand name. The company also provides its activewear products for work and school uniforms and athletic team wear, and other purposes to convey individual, group, and team identity. In addition, it offers undecorated products to branded apparel companies and retailers; and underwear products. Further, the company markets its sock products under the various brands, including Gold Toe, PowerSox, SilverToe, Auro, All Pro, GT, and the Gildan brand. The company was formerly known as Textiles Gildan Inc. and changed its name to Gildan Activewear Inc. in March 1995. Gildan Activewear Inc. was founded in 1984 and is headquartered in Montreal, Canada.

Advisors’ Opinion:

  • [By Eric Volkman]

    Gildan Activewear (NYSE: GIL  ) just bought itself a new wardrobe. The company announced it has acquired “substantially all of the assets” of privately held screen printing and apparel decoration specialist New Buffalo Shirt Factory for around $7 million.

  • [By Tom Stoukas]

    Deutsche Lufthansa AG (LHA) and Allianz SE (ALV) led airlines and insurers lower, retreating at least 1.5 percent. Bayerische Motoren Werke AG (BMW) slid 1.6 percent. Deutsche Bank AG (DBK) rose after JPMorgan Chase & Co. boosted its recommendation on the shares. Gildemeister AG (GIL) added 3.4 percent after Deutsche Bank upgraded the maker of cutting tools.

Best Low Price Stocks To Buy For 2014: Belden Inc (BDC)

Belden Inc. (Belden), incorporated on May 18, 1988, designs, manufactures and markets cable, connectivity, and networking products in markets including industrial, enterprise, and broadcast. The Company operates in three segments: the Americas segment, the Europe, Middle East, and Africa (EMEA) segment and the Asia Pacific segment. The Company’s offers cable, connectivity and networking products, including power generation and distribution, data centers, oil and gas, broadcast, transportation, healthcare and industrial automation. In December 2012, Carlisle Companies Inc acquired Thermax-Raydex business from the Company. In December 2012, the Company sold Consumer Electronics Assets in China to Shenzhen Woer Heat-Shrinkable Material Co Ltd. During the year ended December 31, 2012, the Company acquired Miranda Technologies Inc. (Miranda).

The categories of cable products are copper cables, including shielded and unshielded twisted pair cables, coaxial cables , and stranded cables, fiber optic cables, which transmit light signals through glass or plastic fibers and composite cables, which are combinations of multiconductor, coaxial, and fiber optic cables jacketed together or otherwise joined together to serve complex applications and provide ease of installation. Connectivity products include fiber and copper connectors for the enterprise, broadcast, broadband, and industrial markets. Networking products include Industrial Ethernet switches and related equipment and security features, fiber optic interfaces and media converters used to bridge fieldbus networks over long distances, networking infrastructure for the television broadcast, cable, satellite and IPTV industry, and load-moment indicators for mobile cranes and other load-bearing equipment.

For industrial end markets, the Company supplies cable, connectivity, and networking products for applications ranging from advanced industrial networking and robotics t o traditional instrumentation and control systems. The Compa! ny’s cable products are used in discrete manufacturing and process operations involving the connection of computers, programmable controllers, robots, operator interfaces, motor drives, sensors, printers and other devices. The Company sells its industrial products primarily through value-added resellers, industrial distributors, and original equipment manufacturers (OEMs). It designs, manufactures and markets Industrial Ethernet switches and related equipment, both rail-mounted and rack-mounted, for factory automation, power generation and distribution, process automation, and infrastructure projects, such as bridges, wind farms and airport runways. It also designs, manufactures and markets fiber optic interfaces and media converters. In addition, it designs, manufactures, and markets a range of industrial connectors for sensors and actuators, cord-sets, distribution boxes, and fieldbus communications. These products are used both as components of manufacturing equipment a nd in the installation and networking of such equipment. The Company also designs, manufactures and markets load-moment indicators. Its switches, communications equipment, connectors, and load-moment indicators are sold directly to industrial equipment OEMs and through a network of distributors and system integrators.

For enterprise end markets, the Company supplies structured cabling solutions, connectors, and networking products for the electronic and optical transmission of data, sound, and video over local- and wide- area networks. Products for this market include copper cables including 10-gigabit Ethernet technologies, fiber optic cables, connectors, wiring racks, panels, interconnecting hardware, intelligent patching devices, and cable management solutions for complete end-to-end network structured wiring systems. End-use customers include hospitals, financial institutions, governments, service providers, and data centers. Its systems are installed throug h a network of trained system integrators and are supplied t! hrough au! thorized distributors.

For broadcast end markets, the Company is a provider of hardware and software solutions for the television broadcast, cable, satellite and IPTV industry. Its solutions also span the full breadth of television operations, including production, playout and delivery. The Company also manufactures a variety of multiconductor and coaxial cable and connector products, which distributes audio and video signals for use in broadcast television including digital television and high definition television, broadcast radio, pre- and post-production facilities, recording studios, and public facilities such as casinos, arenas, and stadiums. Its audio/video cables are also used in connection with microphones, musical instruments, audio mixing consoles, effects equipment, speakers, paging systems, and consumer audio products.

The Company manufactures networking infrastructure products for the television broadcast, cable, satellite and IPTV ind ustry. Its primary market channels for this broadcast, music, and entertainment products are broadcast specialty distributors and audio systems installers. It also sells directly to music OEMs and the television networks including ABC, CBS, Fox, and NBC. The Company also provides specialized cables for security applications such as video surveillance systems, airport baggage screening, building access control, motion detection, public address systems, and advanced fire alarm systems. It manufactures flexible, copper-clad coaxial cable and associated connector products for the high-speed transmission of data, sound, and video (broadband) that are used for the drop section of cable television (CATV) systems and satellite direct broadcast systems.

For the broadband end market, Belden manufactures and develops connectivity solutions in several product categories: coax connector products that allow for connections from the provider network to the subscribers’ devic es, hardline connectors that allow service providers to dist! ribute th! eir services within a city, a town or a neighborhood and entry devices that serves to manage and remove network signal noise that could impair performance for the subscriber, and traps and filtering devices that allow service providers to control the signals that are transmitted to the subscriber.

During 2012, the Americas segment contributed approximately 64% of its consolidated revenues. This segment sells the full array of its products for the industrial, enterprise,and broadcast markets. The EMEA segment contributed approximately 19% of its consolidated revenues. This segment sells the full array of its products for the industrial, enterprise,and broadcast markets. The Asia Pacific segment contributed approximately 17% its consolidated revenues. This segment sells the full array of its products for the industrial, enterprise,and broadcast markets.

Advisors’ Opinion:

  • [By Damian Illia]

    Finally, I always like to see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm’s management: the return on equity. The ratio has decreased when compared to its ROE from the same quarter one year prior. Currently, a ROE of 45.9% is higher than all the 1,805 companies in the Diversified Industrials industry. Competitors such General Cable Corp. (BGC) has a very low ROE of 0.3% which is clearly not attractive. An alternative could be Belden Inc (BDC) with a positive ROE of 24%.

  • [By Seth Jayson]

    Belden (NYSE: BDC  ) reported earnings on May 2. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 31 (Q1), Belden met expectations on revenues and beat expectations on earnings per share.

  • [By Rich Duprey]

    Signal transmission specialist Belden  (NYSE: BDC  )  announced yesterday its second-quarter dividend of $0.05 per share, the same rate it has paid since 2004 when it first began making a payout.

Best Low Price Stocks To Buy For 2014: Network Exploration Ltd (NET)

Network Exploration Ltd. is an exploration and development-stage company. The Company’s principal business activities include the exploration of minerals in its mineral properties. It focuses on base and precious metal properties in North and South America. Its activities include the process of exploring its mineral properties, reviewing and subsequently acquiring mineral properties and conducting exploration programs to determine whether these properties contain ore reserves that are recoverable. The Picha copper-silver project is located within the Tertiary Volcanic Arc of Southern Peru. The Pistala project is located east of the NW-SE trending Incapquio fault system in the Department of Tacna, Southern Peru. The Company is in the business of mineral exploration in Canada, Chile and Peru. Network Exploration Chile Limitada is its wholly owned subsidiary. Advisors’ Opinion:

  • [By Holly LaFon]

    The MSCI World Index (Net) is a free float-adjusted market capitalization weighted index that is designed to measure the global equity market performance of developed markets. This benchmark calculates reinvested dividends net of withholding taxes using Luxembourg tax rates. This index is unmanaged and investors cannot invest directly in this index.

  • [By Holly LaFon]

    The MSCI World ex U.S. Small Cap Index (Net) is a free float-adjusted market capitalization index that is designed to measure global developed market equity performance, excluding the U.S. The MSCI Small Cap Indices target 40% of the eligible Small Cap universe within each industry group, within each country. MSCI defines the Small Cap universe as all listed securities that have a market capitalization in the range of USD200-1,500 million. This benchmark calculates reinvested dividends net of withholding taxes using Luxembourg tax rates. This index is unmanaged and investors cannot invest directly in this index.

Best Low Price Stocks To Buy For 2014: Electro Rent Corporation(ELRC)

Electro Rent Corporation engages in the rental, lease, and sale of new and used electronic test and measurement equipment. Its equipment portfolio consists of general purpose test and measurement instruments; personal computers, workstations, and servers; and electrical test equipment and inspection equipment. The company rents or leases its equipment primarily to companies operating in the aerospace, defense, telecommunications, electronics, and semiconductor industries. Electro Rent Corporation serves its customers through sales offices, and calibration and service centers in the United States, Canada, China, and Europe. The company was founded in 1965 and is headquartered in Van Nuys, California.

Advisors’ Opinion:

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Electro Rent (Nasdaq: ELRC  ) , whose recent revenue and earnings are plotted below.

Best Low Price Stocks To Buy For 2014: Kid Brands Inc (KID)

Kid Brands, Inc., incorporated on June 1966, is a designer, importer, marketer and distributor of branded infant and juvenile consumer products. The Company through its wholly owned operating subsidiaries: Kids Line, LLC (Kids Line); LaJobi, Inc. (LaJobi); Sassy, Inc. (Sassy), and CoCaLo, Inc. (CoCaLo) designs and markets branded infant and juvenile products in a number of categories, including, among others: infant bedding and related nursery accessories and decor, nursery appliances, bath/spa products and diaper bags (Kids Line and CoCaLo); nursery furniture and related products (LaJobi), and developmental toys and feeding, bath and baby care items with features that address the various stages of an infant’s early years, including Kokopax line of baby gear (Sassy). In addition to its branded products, it also markets certain categories of products under various licenses, including Carter’s, Disney, Graco and Serta.

The Company’s products are sold prima rily to large, national retail accounts and independent retailers (including toy, specialty, food, drug, apparel and other retailers). The Company maintains relationships with international distributors to service certain retail customers in several foreign countries, as well as with several independent representatives to service select domestic and foreign retail customers. The Company’s infant and juvenile product line consists of approximately 7,400 products that principally focus on newborn to three year old children. It also caters to the age range between three through seven, including toddler bedding and beds, as well as kitchen products. Kids Line products, which are marketed primarily under the Kids Line, Carter’s and Disney brands, and CoCaLo products, which are marketed primarily under the CoCaLo Baby, CoCaLo Couture, and CoCaLo Naturals brands, each consist primarily of infant bedding and related nursery accessories and decor, such as blankets, rugs, mobiles, nightlights, hampers, lamps and wall art, as well as nurser! y appliances, diaper bags and spa/bath products. LaJobi products, which are marketed primarily under the Babi Italia, Europa Baby, Bonavita, Graco and Serta brands, consist primarily of cribs, mattresses and other nursery furniture. Sassy products, which are marketed primarily under the Sassy, Carter’s, Garanimals and Kokopax brands, consist primarily of developmental toys and feeding, bath and baby care items and baby gear with features that address the various stages of an infant’s early years. The Company has five product categories: Hard Good Basics, Soft Good Basics, Toys and Entertainment, Accessories and Decor, and Other. Hard Good Basics includes cribs and other nursery furniture, feeding, food preparation and kitchen products, baby gear and organizers. Soft Good Basics includes bedding, blankets and mattresses. Toys and Entertainment includes developmental toys, bath toys and mobiles. Accessories and Decor includes hampers, lamps, rugs and decor. Other includes all other products that do not fit in the above four categories.

Advisors’ Opinion:

  • [By Eric Volkman]

    Kid Brands (NYSE: KID  ) has put a new individual in the CEO chair. The man formerly occupying that position, Guy Paglinco, will depart in order to, as the company put it, “pursue other activities.” His replacement is James Christl, who will also serve as senior vice president. The transition is effective immediately, although Paglinco will remain a full-time employee of Kid Brands until July 5. Following that, he will make himself available in an advisory capacity for a further six months.